The emergence of dual-action receptor agonists in the management of type 2 diabetes and obesity has sparked considerable interest, particularly regarding retatrutide and tirzepatide. While both medications target both https://umairwzdk213749.estate-blog.com/37755632/retatrutide-vs-tirzepatide-a-comparative-analysis